Emiliem, Inc. Press Release - May 3, 2007

The Van Andel Research Institute and Emiliem Sign Major Translational Medicine and Biomarker Agreement

Strategy directed toward optimal use of novel drug candidates in cancer patients

GRAND RAPIDS, Mich. & EMERYVILLE, Calif—May 3, 2007—The Van Andel Research Institute an independent medical research facility known for its research into the genetic and molecular origins of cancer and other diseases and Emiliem, Inc. a private biotechnology company focused on the discovery and development of molecularly-targeted oncology drugs and their companion biomarkers, announce the signing of an Agreement where Van Andel and Emiliem will work together to translate Emiliem's discoveries into therapies to conquer cancer and enhance lives. Financial details of the multi-year agreement were not disclosed.

"The Van Andel Research Institute has gained worldwide recognition for research in cancer and the discovery and implementation of biomarker strategies for therapeutics. Implementing a translational medicine approach right from the beginning of our research will help us to define a rational biomarker strategy for each drug candidate and to extend this into early targeted therapy clinical trials" said Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem. "Validating the response of specific cancers from patient-derived samples should lead to a rational process where we can conduct clinical trials in patients most likely to respond to specific multi-kinase inhibitors."

"We are very excited about the innovative and streamlined approach that Emiliem takes to drug discovery, as well as the current and future drugs in their pipeline" said Craig Webb, Ph.D., Director of the Program of Translational Medicine at VAI. "Based upon the various drugs targeted mechanisms of action, we plan to evaluate their efficacy in conjunction with the development of a biomarker strategy that can lead to their optimal use in patients"

About Emiliem

Emiliem, Inc. is a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs. The company has developed proprietary drug design technologies that facilitate the inclusion of multiple kinase inhibitor profiles into single compounds. Emiliem's approach to developing targeted drugs includes the ability to identify proprietary biomarkers. Coupling drug discovery with biomarker identification and implementation increases the likelihood of achieving clinical trial endpoints and receiving approval to market these innovative drug candidates. The company is headquartered in Emeryville, California. For more information, visit www.emiliem.com.

About the Van Andel Research Institute

Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. Established by Jay and Betty Van Andel, its goals include identifying new cancer genes and their proteins, developing new methods for detecting cancer before it becomes life threatening, and identifying new biological targets for therapeutic intervention. For more information, visit www.vai.org.

Safe Harbor Statement

This document is intended to provide specific information regarding initiatives of Emiliem, Inc. It is not intended as a general advertisement nor an offer to sell or a solicitation of an offer to buy any securities or an interest in Emiliem, Inc. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Except for historical information, matters described are forward-looking statements that involve risks and uncertainties, including: dependence on third parties for development, regulatory approval, and successful commercialization of products, the inherent risk of failure in developing product candidates based on new technologies, the risks associated with the cost of clinical development efforts, and other risks detailed from time to time in the company's private placement memorandum. Actual results may differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of release of this document. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact:

The Van Andel Research Institute
Joseph P. Gavan
616-234-5053
Joe.Gavan@vai.org

Emiliem, Inc.
Dale E. Johnson
510-316-1197
dale@emiliem.com



	HOME \| ABOUT \| CORPORATE \| BUSINESS MODEL\| PIPELINE \| PRESS \| NEWS \| CONTACT

	Emiliem, Inc. Press Release - May 3, 2007 The Van Andel Research Institute and Emiliem Sign Major Translational Medicine and Biomarker Agreement Strategy directed toward optimal use of novel drug candidates in cancer patients GRAND RAPIDS, Mich. & EMERYVILLE, Calif—May 3, 2007—The Van Andel Research Institute an independent medical research facility known for its research into the genetic and molecular origins of cancer and other diseases and Emiliem, Inc. a private biotechnology company focused on the discovery and development of molecularly-targeted oncology drugs and their companion biomarkers, announce the signing of an Agreement where Van Andel and Emiliem will work together to translate Emiliem's discoveries into therapies to conquer cancer and enhance lives. Financial details of the multi-year agreement were not disclosed. "The Van Andel Research Institute has gained worldwide recognition for research in cancer and the discovery and implementation of biomarker strategies for therapeutics. Implementing a translational medicine approach right from the beginning of our research will help us to define a rational biomarker strategy for each drug candidate and to extend this into early targeted therapy clinical trials" said Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem. "Validating the response of specific cancers from patient-derived samples should lead to a rational process where we can conduct clinical trials in patients most likely to respond to specific multi-kinase inhibitors." "We are very excited about the innovative and streamlined approach that Emiliem takes to drug discovery, as well as the current and future drugs in their pipeline" said Craig Webb, Ph.D., Director of the Program of Translational Medicine at VAI. "Based upon the various drugs targeted mechanisms of action, we plan to evaluate their efficacy in conjunction with the development of a biomarker strategy that can lead to their optimal use in patients" About Emiliem Emiliem, Inc. is a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs. The company has developed proprietary drug design technologies that facilitate the inclusion of multiple kinase inhibitor profiles into single compounds. Emiliem's approach to developing targeted drugs includes the ability to identify proprietary biomarkers. Coupling drug discovery with biomarker identification and implementation increases the likelihood of achieving clinical trial endpoints and receiving approval to market these innovative drug candidates. The company is headquartered in Emeryville, California. For more information, visit www.emiliem.com. About the Van Andel Research Institute Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. Established by Jay and Betty Van Andel, its goals include identifying new cancer genes and their proteins, developing new methods for detecting cancer before it becomes life threatening, and identifying new biological targets for therapeutic intervention. For more information, visit www.vai.org. Safe Harbor Statement This document is intended to provide specific information regarding initiatives of Emiliem, Inc. It is not intended as a general advertisement nor an offer to sell or a solicitation of an offer to buy any securities or an interest in Emiliem, Inc. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Except for historical information, matters described are forward-looking statements that involve risks and uncertainties, including: dependence on third parties for development, regulatory approval, and successful commercialization of products, the inherent risk of failure in developing product candidates based on new technologies, the risks associated with the cost of clinical development efforts, and other risks detailed from time to time in the company's private placement memorandum. Actual results may differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of release of this document. The company disclaims, however, any intent or obligation to update these forward-looking statements. Contact: The Van Andel Research Institute Joseph P. Gavan 616-234-5053 Joe.Gavan@vai.org Emiliem, Inc. Dale E. Johnson 510-316-1197 dale@emiliem.com